Viewing nowPregabalin Oral Dispersible Tablet 75 mg (Pregabalin)
Pregabalin 75mg
Orally disintegrating Tablet · Prescription medication
Huons Co., Ltd.

MFDS item code 202600536 · Approved 2026.02.24
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. Additionally, it provides assistance for partial seizures in epilepsy patients, whether accompanied or not by secondary general symptoms. It is also effective in alleviating symptoms of fibromyalgia. This medication is used to improve symptoms of various neurological disorders.
This medicine should be administered orally as pregabalin in 2 divided doses per day, regardless of food. Place it on the tongue and, once it has disintegrated, swallow without water. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified under the method of administration. b : The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.
This medication may pose a risk of causing mental health issues such as suicidal thoughts or behaviors; therefore, if any changes in mood or behavior occur during treatment, it is essential to inform healthcare professionals immediately. Patients with allergies to this medication or those who have previously shown hypersensitivity to any ingredients should not take it. Diabetic patients may experience weight gain while taking this medication, and may need to adjust their diabetes medications accordingly. If symptoms of angioedema such as facial or oral swelling develop, the medication should be discontinued immediately. Elderly patients should exercise caution while taking this medication as dizziness or drowsiness may increase the risk of falls and injuries; particular care should be taken when first starting treatment. Blurred vision or changes in eyesight may occur; if these symptoms appear, consultation with a healthcare professional is advised. When switching from another antiepileptic drug to this medication solely, as there is a lack of sufficient data, it should be done under professional guidance. Abrupt discontinuation of this medication may cause withdrawal symptoms such as insomnia, headache, anxiety, depression, or seizures; therefore, it should be tapered gradually according to healthcare professionals’ instructions. Patients with a history of substance abuse may be at increased risk of dependency on this medication and should take precautions. Dosing adjustments may be necessary for patients with impaired renal function. Patients with severe cardiac disease should use this medication cautiously as it may exacerbate heart issues such as congestive heart failure. Concurrent use with opioids may enhance central nervous system depressant effects; therefore, caution is warranted. Patients with compromised respiratory function or the elderly may have a significant risk of severe respiratory depression and should only use the medication after consulting with a healthcare professional. In early pregnancy, there may be a risk of congenital malformations to the fetus, so women who are pregnant or planning to become pregnant must consult with a healthcare professional and use effective contraception. Lactating women should be aware that this medication can pass into breast milk and may affect the infant, hence breastfeeding should be avoided or a discussion with healthcare providers is necessary during treatment. When engaging in hazardous activities such as driving or operating machinery, care should be taken due to the risk of accidents from dizziness or drowsiness. If severe skin rashes, blisters, or red spots occur while taking this medication, it should be discontinued immediately and healthcare professionals should be informed. In cases of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, necessitating immediate emergency treatment. Keep out of reach of children and avoid transferring to other containers, as this could affect the quality of the medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from exposure to air and moisture. It’s advisable to maintain a storage temperature between 1 degrees and 30 degrees Celsius.
Light orange rhomboid oral dispersible tablet
30 tablets/PTP [(10 tablets/PTP × 3)], 100 tablets/PTP [(10 tablets/PTP × 10)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Orally disintegrating Tablet · Prescription medication
Huons Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.